NHS National Pharmaceuticals - Everolimus and terminated agreement products
The NHS Commissioning Board (operating under the name of NHS England)contractFind a Tender ↗Ref ocds-h6vhtk-02a47132014L0024active
Estimated value
—
goods
Awarded value
—
Suppliers
45
21 SME
Lots
3
45 awarded
Published
28 Sept 2021
Description
Potential periods of call-offs under the framework agreement:Everolimus: All regions: to commence as soon as possible with an end date of 01/03/2022Oral Products: All regions: to commence as soon as possible with an end date of 28/02/2022Hospital Only Products: DLS, DNE, DNW, DLN and DSW regions: to commence as soon as possible with an end date 31/01/2022
Scope
- Reference
- CM/PHG/21/5632
- Commercial tool
- Standalone contract
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- UK
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| — | — | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 45 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Awarded to
Lots · 3 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 2 | Lot 2 - CM/PHG/21/5632/01 Oral (plus non parenteral) products | — | cancelled |
| 1 | Lot 1 - CM/PHG/21/5632/00 Everolimus | — | cancelled |
| 3 | Lot 3 - CM/PHG/21/5632/02 Hospital Only products | — | cancelled |